Other entities

Reports category: reports-from-other-entities

  1. Home
  2. Reports
  3. Other entities

Report on savings on generic and biosimilar drugs in the US.

Other entities Biosim
read more

EMA Annual Report 2022

Other entities Biosim
read more

Monograph "Real world evidence: Abstract library"

Other entities Biosim
read more

Trends in the field of biosimilars in the United States

Other entities Biosim
read more

Analysis of US Health Savings from Generics and Biosimilars in 2021

Other entities Biosim
read more

Improving Understanding and Acceptance of Biosimilars in the United States

Other entities Biosim
read more

Biosimilars in the treatment of solid tumors

Other entities Biosim
read more

The US Generic & Biosimilar Medicines Savings Report

Other entities Biosim
read more

Education in Biosimilars - Whitepaper

Other entities Biosim
read more

What do we know about biosimilar biologics?

Other entities Biosim
read more

Communication in biosimilar biologics

Other entities Biosim
read more

Variability in the adoption of biosimilars

Other entities Biosim
read more

Hospital expenditure of the National Health System: pharmacy and investment in capital goods

Other entities Biosim
read more

Biosimilars in the United States 2020–2024 COMPETITION, SAVINGS, AND SUSTAINABILITY

Other entities Biosim
read more

Biosimilars, for value-based healthcare

Other entities Biosim
read more

Country Scorecards for Biosimilar Sustainability

Other entities Biosim
read more

Biosimilars in the European Union

Other entities Biosim
read more

Biosimilars Action Plan: Balancing Innovation and Competition

Other entities Biosim
read more

What do I need to know about Biosimilar Medicines. Information for patients.

Other entities Biosim
read more

What you should know about biosimilar medicines. European Commission Consensus Report

Other entities Biosim
read more

    BioSim Newsletter

    Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

    SUBSCRIBE